Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- LIPO
- Price
- 0.17
- Stock movement down
- -0.03 (-14.01%)
- Company name
- Lipella Pharmaceuticals Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 762.90K
- Ent value
- -992.79M
- Price/Sales
- 0.00
- Price/Book
- 0.00
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -95.89%
- 3 year return (CAGR)
- -80.10%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
LIPO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.00 |
| Price to Book | 0.00 |
| EV to Sales | -4.59 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 4.62M |
| EPS (TTM) | -276.57 |
| FCF per share (TTM) | -519.14 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 216.29M |
| Gross profit (TTM) | -3.39M |
| Operating income (TTM) | -1.28B |
| Net income (TTM) | -1.26B |
| EPS (TTM) | -276.57 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -1.57% |
| Operating margin (TTM) | -591.06% |
| Profit margin (TTM) | -581.70% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.86B |
| Net receivables | 0.00 |
| Total current assets | 2.08B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 403.12K |
| Total assets | 2.35B |
| Accounts payable | 462.89M |
| Short/Current long term debt | 264.08M |
| Total current liabilities | 642.40M |
| Total liabilities | 862.22M |
| Shareholder's equity | 1.49B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.36B |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -2.36B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -84.58% |
| Return on Assets | -53.54% |
| Return on Invested Capital | -82.13% |
| Cash Return on Invested Capital | -154.17% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.17 |
| Daily high | 0.17 |
| Daily low | 0.17 |
| Daily Volume | 0K |
| All-time high | 37.68 |
| 1y analyst estimate | 10.00 |
| Beta | -0.08 |
| EPS (TTM) | -276.57 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 25 Feb 2026 |
Downside potential
Loading...
Downside potential data
| LIPO | S&P500 | |
| Current price drop from All-time high | -99.56% | -1.82% |
| Highest price drop | -99.61% | -56.47% |
| Date of highest drop | 22 Jan 2026 | 9 Mar 2009 |
| Avg drop from high | -80.89% | -10.84% |
| Avg time to new high | 396 days | 12 days |
| Max time to new high | 791 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
762.90K
Marketcap category
Small-cap
Description
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Employees
5
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner